Skip to main content
Contact Locations Diversity Pro Bono Why Wolf

Two Wolf Greenfield Attorneys Recognized as Global Leaders in IP

2 min read

Two Wolf Greenfield shareholders have been included in the 2026 edition of the IAM Strategy 300: Global Leaders. This guide showcases the world’s top intellectual property minds whose approach to IP is regarded by peers as truly strategic in nature. It acknowledges leaders from across in-house, private practice, and service provider roles who merit special attention for their experience in creating, protecting, managing, transacting, and enforcing critical patent rights.

Scott focuses his practice on post-grant patent counseling and litigation matters at the US Patent and Trademark Office (USPTO) and related appeals to the US Court of Appeals for the Federal Circuit (CAFC). Scott handles all aspects of post-issuance patent proceedings, with a particular focus on administrative trials before the Patent Trial and Appeal Board (PTAB), such as inter partes review (IPR), post-grant review (PGR), and patent reexamination. He also provides advice on USPTO post-grant proceedings concurrent with complex International Trade Commission (ITC) and district court litigations. Scott is one of the most active PTAB trial attorneys in the US, having handled more than 500 PTAB matters, including competitor disputes in which significant market share/damage liability was at stake (e.g., $500 million+). He currently serves as lead post-grant counsel to some of the world’s best-known innovators. Scott also serves as an adjunct professor at the George Washington University School of Law in Washington, DC. 

Rob develops strategies for life science companies to maximize exclusivity for therapeutic and diagnostic products. He assists clients with building global patent portfolios aligned with product life cycle, and advises clients on regulatory exclusivities, patent term extensions, Orange Book listings, and biosimilars. In addition to pharma and biotech companies, Rob works with universities, research institutions, and venture capital investors, providing patentability and freedom-to-operate assessments, non-infringement and invalidity opinions, performing IP diligence, and preparing agreements. He regularly counsels federal grant recipients and contractors with Bayh-Dole compliance, including use of iEdison. Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics, and small molecules for new disease indications.

IAM Strategy 300 Global Leaders draws from the worlds of private practice, consulting, and other service providers, with practitioners from the major IP markets in North America, Europe, and Asia. IAM’s research team gathers thousands of external nominations and corresponds with attorneys and their clients over a five-month period to compile the list.
Top